<DOC>
	<DOC>NCT01744912</DOC>
	<brief_summary>The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy</brief_summary>
	<brief_title>Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Relapsed or refractory Bcell nonHodgkins Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients must have received at least one prior line of therapy with an antiCD20 antibody (i.e. rituximab, ofatumumab, etc.) or an antiCD20 antibody containing regimen Measurable or evaluable Disease Eastern Cooperative Oncology Group performance status 0, 1 or 2 Patients ineligible for high dose or combination chemotherapy + stem cell transplant No active or chronic infection of Hepatitis B or C and no history of HIV based on negative serology All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry Prior autologous or allogeneic stem cell transplantation within 6 months of study entry History of severe hypersensitivity or anaphylaxis to prior murine or mouse/human chimeric antibodies, or to any component of ublituximab, or with prior lenalidomide or thalidomide Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements History of deep vein thrombosis (DVT) or pulmonary embolus (PE) in the six months prior to Day 1 of Cycle 1 Pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>immunomodulatory agent</keyword>
	<keyword>ublituximab</keyword>
	<keyword>lenalidomide</keyword>
</DOC>